|1.||Guan, Xin-Yuan: 6 articles (01/2011 - 06/2004)|
|2.||Xie, Dan: 5 articles (05/2009 - 06/2004)|
|3.||Kung, Hsiang-Fu: 4 articles (05/2009 - 01/2008)|
|4.||Chen, Wei: 3 articles (11/2015 - 02/2009)|
|5.||Luo, Jun-Hang: 3 articles (05/2009 - 02/2009)|
|6.||Zeng, Yi-Xin: 3 articles (05/2009 - 02/2009)|
|7.||Hua, Wen-Feng: 3 articles (05/2009 - 02/2009)|
|8.||Ma, Ning-Fang: 2 articles (01/2008 - 06/2004)|
|9.||Du, Feiya: 1 article (11/2015)|
|10.||Liu, Yu: 1 article (11/2015)|
|1.||Breast Neoplasms (Breast Cancer)
11/01/2015 - "The eIF-5A2 expression levels varied among breast cancer cells. "
11/01/2015 - "However, eIF-5A2 overexpression in breast cancer and its effect on chemotherapy are unknown. "
11/01/2015 - "Silencing of eIF-5A2 significantly improved doxorubicin toxicity in all three breast cancer cell lines. "
11/01/2015 - "This study shows that eIF-5A2 plays an important role in doxorubicin chemoresistance in breast cancer cells."
11/01/2015 - "We measured eIF-5A2 expression and doxorubicin sensitivity in different human breast cancer cell lines (Bcap-1937, HCC1937, and MCF-7). "
01/01/2011 - "Functional study has demonstrated the oncogenic role of eIF-5A2 in the initiation and progression of human cancers. "
07/24/2015 - "Remarkably, our results also demonstrate that the cancer-associated isoform eIF-5A2 is dispensable for normal development and viability. "
01/01/2011 - "Instead of resulting in spontaneous tumor formation, overexpression of eIF-5A2 accelerated the aging process in adult transgenic mice. "
05/01/2009 - "These findings suggest that overexpression of EIF-5A2, as detected by IHC, may predict tumor recurrence and progression in pTa/pT1 UC patients, and the protein expression of eIF-5A2 might be regulated not only by gene amplification, but also by other molecular mechanisms."
05/01/2009 - "Importantly, multivariate Cox regression analysis revealed that EIF-5A2 expression provided a significant independent prognostic parameter either in tumor recurrence (P = 0.002) or in tumor progression (P = 0.007). "
05/01/2009 - "The authors investigated the status of abnormalities of eIF-5A2 gene in superficial (pTa/pT1) urothelial carcinoma of the bladder (UC), as well as its correlation with clinicopathologic variables and patient outcome. "
02/01/2009 - "In univariate survival analysis of the ovarian carcinoma cohorts, a significant association of overexpression of EIF-5A2 with shortened patient survival (mean 39.0 months vs 69.5 months, p<0.001) was demonstrated. "
02/01/2009 - "Amplification of eIF-5A2 was detected in 16% of informative ovarian carcinomas. "
02/01/2009 - "The amplification status of eIF-5A2 in each ovarian carcinoma was assessed by fluorescence in situ hybridization. "
02/01/2009 - "Abnormalities of eIF-5A2 and its clinical/prognostic significance, however, in ovarian carcinoma are unclear. "
|4.||Colorectal Neoplasms (Colorectal Cancer)
01/01/2008 - "These findings suggest that overexpression of EIF-5A2 in colorectal carcinomas may be important in the acquisition of a metastatic phenotype and plays an important role in colorectal carcinoma development and progression."
01/01/2008 - "In primary colorectal carcinomas, the frequency of EIF-5A2 overexpression was significantly higher in colorectal carcinomas with lymphovascular invasion (61.2%) than that in colorectal carcinomas without lymphovascular invasion (36.6%, P < .05). "
01/01/2008 - "Amplification of eIF-5A2 was detected in 15.8% (16/101) of informative colorectal carcinomas, and most of them showed overexpression of EIF-5A2. "
01/01/2008 - "Abnormalities of eIF-5A2, however, in colorectal carcinoma are unclear. "
01/01/2008 - "Overexpression of EIF-5A2 is associated with metastasis of human colorectal carcinoma."
02/01/2009 - "In this study, we examined expression of EIF-5A2, using immunohistochemistry, in 30 normal ovaries, 30 ovarian cystadenomas, 30 borderline ovarian tumors and 110 ovarian carcinomas. "
02/01/2009 - "Overexpression of EIF-5A2 was detected in none of the normal ovaries, 7% cystadenomas, 30% borderline tumors, and 53% invasive ovarian carcinomas, respectively. "
|3.||Peptide Initiation Factors (Initiation Factor)
|9.||eukaryotic translation initiation factor 5A
|2.||Drug Therapy (Chemotherapy)